Show simple item record

dc.contributor.authorRYDER, SHEILAen
dc.date.accessioned2013-07-11T13:57:26Z
dc.date.available2013-07-11T13:57:26Z
dc.date.issued2003en
dc.date.submitted2003en
dc.identifier.citationGilmer JF, Murphy MA, Shannon JA, Breen CG, Ryder SA, Clancy JM, Single oral dose study of two isosorbide-based aspirin prodrugs in the dog, J Pharm Pharmacol, 55, 10, 2003, 1351 - 1357en
dc.identifier.otherYen
dc.descriptionPUBLISHEDen
dc.descriptionPMID: 14607016en
dc.description.abstractThe objective of this study was to compare two aspirin prodrugs, isosorbide diaspirinate (ISDA) and a nitroaspirin (ISMNA), with aspirin in terms of effects on dog platelet function after administration of a single oral dose. Groups of six dogs were administered ISDA (2 mg kg?1), ISMNA (4 mg kg?1) or aspirin (2 mg kg?1). Blood was sampled at 1, 2, 4, 8, 12 and 24 h post-dosing and evaluated for capacity to generate post-clotting thromboxane (TX)B2. The aggregation response to arachidonic acid (AA) (100 ?M), ADP (30 ?M) or collagen (10 ?g mL?1) was estimated at each time-point using the whole blood impedance method. Plasma ISMN following oral administration of ISMNA was also measured and compared with plasma ISMN following administration of a physical mixture of ISMN and aspirin. ISDA administration (2 mg kg?1) was associated with a significant reduction (P< 0.05) in serum TXB2 at 12 and 24 h (>90%) post-dosing and persistent inhibition of AA-induced platelet aggregation. ISDA administration caused a more marked depression of post-clotting TXB2 levels than aspirin in this study, although its ability to inhibit platelet aggregation was less consistent than that of aspirin. The nitroaspirin ISMNA was least effective at inhibiting platelet aggregation response or TXB2 production. The ISMN AUC0?24h for the ISMNA-treated dogs was 77% of that for the physical mix-treated dogs and the tmax was delayed. This study indicates that the two aspirin esters cause aspirin-like effects on platelet function, probably through aspirin release, when administered orally to dogs.en
dc.format.extent1351en
dc.format.extent1357en
dc.language.isoenen
dc.relation.ispartofseriesJ Pharm Pharmacolen
dc.relation.ispartofseries55en
dc.relation.ispartofseries10en
dc.rightsYen
dc.subjectisosorbideen
dc.subjectaspirinen
dc.subjectprodrugen
dc.subjectdogen
dc.subjectnitroaspirinen
dc.subjectplatelet aggregationen
dc.subjectacetylsalicylic aciden
dc.subject.lcshAspirinen
dc.subject.lcshBlood platelets--Aggregationen
dc.subject.lcshacetylsalicylic aciden
dc.subject.lcshDrug developmenten
dc.subject.lcshPharmacokineticsen
dc.titleSingle oral dose study of two isosorbide-based aspirin prodrugs in the dogen
dc.typeJournal Articleen
dc.type.supercollectionscholarly_publicationsen
dc.type.supercollectionrefereed_publicationsen
dc.identifier.peoplefinderurlhttp://people.tcd.ie/sryderen
dc.identifier.rssinternalid17363en
dc.identifier.doihttp://dx.doi.org/10.1211/0022357022007en
dc.identifier.urihttp://hdl.handle.net/2262/66704


Files in this item

Thumbnail
Thumbnail

This item appears in the following Collection(s)

Show simple item record